事業内容
あなたはここにいる:ホーム > 事業内容 > Integrated Projects > Medicilon Preclinic...
Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.
Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare.
Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.
类别 | CAR-T Cell | TCR-T Cell | CAR-NK Cell |
DNT Cell | TIL Cell |
A target
B target
A target & B target
The picture shows the pharmacodynamic study of dual-target CAR-T cells in K 562 subcutaneously transplanted tumor mouse model
The picture shows the pharmacodynamic study of the mouse pharmacodynamic model of hPBMC immune system reconstruction induced by Raji-luc fluorescein-labeled lymphoma cells
The parmacokinetc research studies sample in vivo behaviors, such as distribution, proliferation and survival time. We also track transgenic product expressed and secreted outside the immune cells, if any, to provide its local and/or systemic exposure characteristics.
The non-clinical safety studies of cellular immunotherapies are mainly designed and carried out based on the potential safety risks of the drugs. In addition to the common safety risks, cell therapies may also contain the risks of:
関連研究室